Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...

With a buyout of scPharmaceuticals worth up to $360 million, MannKind is looking to dive into the large and growing field of cardiometabolic treatments. Endocrine and orphan lung disease-focused ...

CPTX2309 is a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells mRNA-based approach is designed to achieve rapid, deep, and transient B ...

When you pop a prescription pill into your mouth, you trust it to address the issue it was meant to fix. But what really happens? How is your body processing the drugs and what happens if the dosage ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment of ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...

Comparative Outcomes of Veno-Arterial ECMO (VA-ECMO) vs. IMPELLA vs. Combining VA-ECMO With IMPELLA (ECPELLA) in Cardiogenic Shock Receive the the latest news, research, and presentations from major ...

Supernus Pharmaceuticals, Inc. announced that the FDA has approved an updated label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data, highlighting its serotonin 5 ...

Background: Obesity is increasingly prevalent in patients with heart failure (HF). Subcutaneous (SC) furosemide (Furoscix) is available as a 5-hour SC infusion via an on-body delivery device for the ...

Lokelma (sodium zirconium cyclosilicate) is a brand-name powder that’s prescribed for high potassium levels. Lokelma has interactions with other drugs and supplements. Examples include furosemide ...